
Employee benefits captives: a growing market with billions in premium at stake
As employers seek greater control over rising healthcare costs and global benefit spend, employee benefits captives are gaining momentum. Captive Review investigates the market’s growth, the opportunities presented by US medical stop-loss and the challenges of measuring its true size.
Employee benefits are emerging as an increasingly important application for captive insurance as multinational employers seek greater control over costs, coverage and data across global programmes. At the same time, the expansion of medical stop-loss captives in the US is opening another substantial market for employers looking to retain more healthcare risk.
Although these segments operate differently, both reflect a wider shift towards alternative approaches to financing employee-related risks.
The scale of the opportunity is significant. In June 2026, Marsh reported that more than 140 companies were using captives for international employee benefits, representing more than $3 billion in premium. The broker said the number of companies using captives for international employee benefits had more than doubled over the previous five years.
Meanwhile, the US medical stop-loss insurance market reached $39 billion in premium in 2024, according to Oliver Wyman and Guy Carpenter's annual market update.
These figures measure different aspects: Marsh’s figure relates to international employee-benefit captive programmes, while the $39 billion figure represents the wider US medical stop-loss insurance market, not premium written by captives alone. They should therefore be considered separate indicators of the opportunity, rather than combined into a single market valuation.
“The potential US medical stop-loss market includes approximately 200,000 clients.”
International employee benefits gain momentum
The international employee benefits captive market remains relatively small compared with the wider captive industry, but several indicators point to accelerating adoption.
MAXIS Global Benefits Network reported approximately 33% growth over the preceding two years in both the number of captives in its portfolio and the premium written through its captive programmes. The network serves multinational employers through local insurance partners, helping them manage employee benefits across multiple countries.
Aon also reported that 31% of respondents to its 2025 Global Benefits Trends Study were considering a captive for employee benefits, compared with 26% in 2024.
The attraction extends beyond premium savings. Aon identifies financial control, flexibility in benefit design and improved governance as key reasons employers consider employee benefits captives. Greater access to claims data can help employers understand workforce health risks and identify opportunities to improve the design and management of their programmes.
The risks being financed can include group life, disability, accident and international medical benefits. For multinational companies, a captive can provide a central mechanism for managing risks that would otherwise sit across numerous local insurance arrangements.
Marsh's international employee benefits captive solution, for example, is designed to finance and reinsure medical, life, disability and accident benefits across multiple countries. Such arrangements can improve transparency over programme performance and give employers greater control over pricing, renewals and coverage.
Medical stop-loss creates a larger US opportunity
In the US, medical stop-loss captives address a different part of the employee benefits market. Many employers self-fund their healthcare plans, paying routine claims themselves while purchasing stop-loss insurance to protect against claims exceeding specified thresholds. Group captives allow participating employers to share elements of this risk and potentially benefit from collective risk management and underwriting performance.
The underlying insurance market has expanded rapidly. Guy Carpenter’s 2024 stop-loss market analysis estimates that medical stop-loss premium rose from approximately $16.9 billion in 2017 to $35.5 billion in 2023. Oliver Wyman's subsequent analysis puts the market at $39 billion in 2024.
The expansion reflects rising healthcare costs, increased adoption of self-funded employer health plans and pressure from high-cost claims. Wyman’s analysis highlights the growing frequency of claims exceeding $1 million, including those associated with cancer treatment, premature births and specialty therapies.
This creates a challenging environment for employers and insurers alike. Self-funding can increase employer control over healthcare expenditure, but it also exposes them to substantial volatility when individual claims become exceptionally large. Stop-loss insurance transfers some of that exposure, while captive arrangements can provide an additional mechanism for retaining and pooling risk.
The opportunity for captives is substantial, although the entire $39 billion market is not captive business. Conventional insurers continue to write much of the premium and the available figures do not establish the captive share of the total market.
There are, however, indications of considerable room for further adoption. Captive International has reported Captive Resources' estimate that the potential US medical stop-loss market includes approximately 200,000 clients. The estimate suggests a large potential customer base, although it is a provider’s assessment of market potential rather than an independently measured industry total.
Captive Resources’ scale also illustrates the maturity of the broader group-captive model. Its portfolio includes medical stop-loss and casualty programmes, but its aggregate premium and membership figures should not be mistaken for medical stop-loss figures alone.
Different markets, similar commercial drivers
International employee benefits captives and US medical stop-loss captives serve different employer needs.
International programmes are generally relevant to multinational organisations seeking to consolidate and finance benefits risks across jurisdictions. Their complexity lies in coordinating local insurers, regulations, claims information and benefit structures. Medical stop-loss captives, by contrast, are closely linked to US employers’ decisions to self-fund healthcare and retain a share of their claims risk.
Nevertheless, both models respond to a common set of pressures: rising benefit costs, the desire for greater financial control and the need for better information about claims and risk.
For international programmes, the benefits of captive participation can extend to improved global oversight and the ability to adapt benefit design to local workforce needs. In the US, the focus is more directly on managing healthcare claims volatility and structuring the relationship between self-funded plans, stop-loss protection and retained risk.
This distinction matters when assessing the commercial opportunity. The $3 billion-plus Marsh figure provides evidence of existing international employee benefits captive premium, while the $39 billion stop-loss figure describes a far broader insurance market from which captive arrangements might attract business. Neither number alone establishes the total premium currently written through employee benefits captives worldwide.
Cell captives lower the barriers to entry
One development affecting international employee benefits is the growing availability of structures designed to make captive participation more accessible.
Marsh launched its Nexus solution in June 2026 as a protected cell captive structure designed for multinational employers with more than $3 million in annual employee benefits expenditure outside the US. It aims to provide access to captive financing without requiring each employer to establish an entirely separate captive.
Aon similarly identifies cell structures as a way to reduce set-up and operating costs and governance requirements, allowing employers to begin with selected benefit programmes and expand over time.
This is important because the traditional standalone model can require significant capital, specialist expertise and administrative resources. A cell structure can provide a more accessible entry point for employers whose international benefits expenditure might justify risk retention but not the creation of a dedicated captive.
MAXIS is pursuing a similar direction for companies that may not yet be ready to establish their own captive. In an interview with Captive Review in July 2026, its CEO discussed the network's more than 80 multinational employee benefits captive programmes and the potential for multi-employer arrangements to help mid-market companies develop towards more sophisticated captive structures.
In the US, group medical stop-loss captives offer another route for employers seeking to participate in collective risk financing. Their appeal depends on factors including employer size, claims experience, risk appetite and the structure of the captive's retained and reinsured layers.
Growth potential, but no single market-size figure
The available evidence points to employee benefits becoming a more important area of captive activity, but a definitive global market-size figure remains elusive.
Marsh's more than $3 billion in international employee benefits premium is a useful measure of an established market. The US medical stop-loss market's $39 billion in 2024 premium demonstrates the scale of the underlying insurance opportunity, but it cannot be treated as captive premium. The populations also overlap across brokers, networks and captive managers, so their figures should not simply be added together.
Demand indicators are encouraging. Aon's survey found that 31% of respondents were considering an employee benefits captive in 2025, up from 26% a year earlier, while MAXIS reported approximately 33% growth in its captive portfolio and associated premium over two years.
These measures are not directly comparable: one records stated interest while the other reflects growth within a particular network. Together, however, they indicate momentum across international employee benefits risk financing.
The strategic rationale is strengthening as employers face rising healthcare costs, pressure to maintain competitive benefits and demands for better financial transparency. Captives offer a way to connect those priorities with risk retention and insurance purchasing decisions.
For the captive industry, the opportunity is twofold. International employee benefits offer a growing route for multinational employers to consolidate and finance life, disability, accident and medical risks. US medical stop-loss offers a large adjacent market in which group captives can help employers manage self-funded healthcare exposure.
The two segments should remain distinct in any market-sizing exercise. But both suggest that employee-related risks could become an increasingly important source of captive growth as employers seek more flexible, data-driven and financially sustainable approaches to benefits financing.
Did you get value from this story? Sign up to our free newsletters and get stories like this sent straight to your inbox.
